Familial isolated hyperparathyroidism
fuh-MEE-lee-uhl eye-SOH-lay-tid HY-per-PAR-uh-THY-roid-izm
Also known as: FIHP, Hereditary primary hyperparathyroidism
At a Glance
What is Familial isolated hyperparathyroidism?
Familial isolated hyperparathyroidism is a rare genetic condition that affects the parathyroid glands, which are responsible for regulating calcium levels in the body. It is caused by mutations in specific genes that lead to overactivity of these glands. Over time, this can result in high levels of calcium in the blood, a condition known as hypercalcemia. Early symptoms may include fatigue, weakness, and bone pain, while later stages can lead to kidney stones, osteoporosis, and cognitive disturbances. Early diagnosis is critical to prevent complications and manage symptoms effectively. This condition can have significant implications for family life, as it is inherited and may affect multiple family members. The prognosis varies depending on the severity and management of the condition, but with appropriate treatment, individuals can lead relatively normal lives. Daily life may involve regular monitoring of calcium levels, medication to manage symptoms, and potentially surgical intervention to remove overactive glands. Support from healthcare providers and genetic counseling can help families understand and cope with the condition. Lifestyle adjustments, such as dietary changes and regular exercise, may also be recommended to manage symptoms. Despite the challenges, many individuals with familial isolated hyperparathyroidism can maintain a good quality of life with proper care.
Medical Definition
Familial isolated hyperparathyroidism is characterized by hypersecretion of parathyroid hormone due to genetic mutations, leading to hypercalcemia. Pathologically, it involves hyperplasia or adenomas of the parathyroid glands. Histological findings typically show chief cell hyperplasia or adenomatous changes. It is classified under hereditary hyperparathyroidism syndromes, distinct from other syndromes like MEN1 or MEN2. Epidemiologically, it is a rare disorder with an autosomal dominant inheritance pattern. The disease course can vary, but it often requires lifelong management to prevent complications associated with prolonged hypercalcemia.
Familial isolated hyperparathyroidism Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Hypercalcemia manifests as elevated calcium levels in the blood, often leading to fatigue, confusion, and muscle weakness. This condition is caused by excessive secretion of parathyroid hormone (PTH), which increases calcium release from bones, absorption in the intestines, and reabsorption in the kidneys. Over time, persistent hypercalcemia can lead to complications such as kidney stones and osteoporosis. It affects daily life by causing chronic fatigue and cognitive difficulties, and management includes hydration, medications, and sometimes surgery.
Bone pain is a result of increased bone resorption due to elevated PTH levels, leading to weakened bones. The biological mechanism involves PTH stimulating osteoclasts, which break down bone tissue and release calcium into the bloodstream. As the condition progresses, the pain may become more severe and persistent, affecting mobility and quality of life. Pain management includes analgesics, bisphosphonates, and addressing the underlying hyperparathyroidism.
Muscle weakness occurs due to the effects of hypercalcemia on neuromuscular function, leading to decreased muscle contraction efficiency. Elevated calcium levels interfere with normal neuromuscular transmission and muscle fiber function. Over time, this can result in significant muscle atrophy and decreased physical activity. Daily life is impacted by reduced strength and endurance, and treatment focuses on correcting calcium levels and physical therapy.
Common
Kidney stones form when high calcium levels lead to crystallization in the kidneys, causing severe pain and urinary issues. The biological mechanism involves hypercalciuria, where excess calcium is excreted in the urine, promoting stone formation. If untreated, kidney stones can recur and cause kidney damage over time. Management includes increased fluid intake, dietary changes, and sometimes surgical intervention.
Abdominal pain can occur due to hypercalcemia-induced gastrointestinal disturbances, including constipation and peptic ulcers. The elevated calcium levels affect smooth muscle contraction and gastric acid secretion. Over time, this can lead to chronic digestive issues and discomfort. Treatment involves managing calcium levels and symptomatic relief with medications.
Depression is a psychological symptom that may arise from the biochemical imbalances caused by hypercalcemia. The mechanism involves altered neurotransmitter function and brain chemistry due to elevated calcium levels. Chronic depression can significantly affect mental health and daily functioning. Management includes addressing the underlying calcium imbalance and psychological support.
Less Common
Hypertension may develop as a result of increased calcium levels affecting vascular smooth muscle tone and renal function. The biological mechanism involves calcium-mediated vasoconstriction and altered kidney function. Over time, untreated hypertension can lead to cardiovascular complications. Management includes antihypertensive medications and controlling calcium levels.
Pancreatitis can occur due to hypercalcemia-induced activation of pancreatic enzymes, leading to inflammation. The elevated calcium levels can precipitate enzyme activation within the pancreas. If recurrent, pancreatitis can cause significant digestive issues and chronic pain. Treatment involves managing calcium levels and supportive care for pancreatic inflammation.
What Causes Familial isolated hyperparathyroidism?
Familial isolated hyperparathyroidism (FIHP) is primarily associated with mutations in the MEN1, CDC73, and CASR genes, located on chromosomes 11q13, 1q31.2, and 3q13.3-q21, respectively. The MEN1 gene encodes menin, a tumor suppressor protein that regulates gene transcription, DNA repair, and cell proliferation. Mutations in MEN1 can lead to loss of function, disrupting cell cycle control and promoting parathyroid cell proliferation. The CDC73 gene encodes parafibromin, a component of the PAF1 complex involved in transcriptional regulation and histone modification. Mutations in CDC73 impair parafibromin function, leading to dysregulation of gene expression and increased cell growth. The CASR gene encodes the calcium-sensing receptor, which regulates parathyroid hormone secretion in response to blood calcium levels. Mutations in CASR can alter receptor function, leading to inappropriate parathyroid hormone release. These genetic disruptions result in hyperplasia or adenoma formation in the parathyroid glands, causing excessive parathyroid hormone production. The overproduction of parathyroid hormone leads to hypercalcemia, affecting bone resorption, renal tubular reabsorption, and intestinal calcium absorption. Neuroinflammation and immune responses are not directly implicated in FIHP, but chronic hypercalcemia can affect neurological function. White matter degeneration is not a primary feature of FIHP, but prolonged hypercalcemia can lead to neurological symptoms. Symptoms of FIHP, such as bone pain, kidney stones, and neuromuscular dysfunction, arise from hypercalcemia and vary based on mutation type and environmental factors. Disease severity varies due to genetic heterogeneity, modifier genes, and lifestyle factors influencing calcium metabolism.
How is Familial isolated hyperparathyroidism Diagnosed?
Typical age of diagnosis: Familial isolated hyperparathyroidism is typically diagnosed in early adulthood, often between the ages of 20 and 40, when patients present with symptoms of hypercalcemia or are identified through family screening.
Clinicians look for symptoms such as fatigue, depression, and kidney stones. A detailed family history is crucial to identify potential hereditary patterns. Physical examination may reveal bone tenderness or muscle weakness. This step helps to determine the likelihood of a hereditary condition and guides further testing.
Ultrasound and sestamibi scans are commonly used imaging modalities. These studies may show enlarged parathyroid glands or ectopic parathyroid tissue. Imaging findings can confirm the presence of hyperparathyroidism and exclude other causes of hypercalcemia. Differential diagnoses such as parathyroid carcinoma or secondary hyperparathyroidism are considered.
Serum calcium and parathyroid hormone (PTH) levels are the primary tests ordered. Elevated calcium and PTH levels are indicative of hyperparathyroidism. Abnormal results prompt further investigation into familial patterns. These results guide the decision to pursue genetic testing.
Genes such as MEN1, CDC73, and CASR are sequenced to identify mutations. Mutations like missense or nonsense changes are commonly found. Positive genetic results confirm the diagnosis of familial isolated hyperparathyroidism. Results also provide information for family counseling and risk assessment.
Familial isolated hyperparathyroidism Treatment Options
Cinacalcet is a calcimimetic agent that reduces parathyroid hormone levels by increasing the sensitivity of the calcium-sensing receptor. It is used to manage hypercalcemia in patients with hyperparathyroidism. Clinical trials have shown its efficacy in reducing serum calcium levels. Limitations include gastrointestinal side effects and the need for regular monitoring. It is not curative and is typically used when surgery is not an option.
Techniques such as weight-bearing and resistance exercises are employed. The goal is to improve bone density and reduce fracture risk. Sessions are typically conducted 2-3 times per week for optimal benefits. Outcomes are measured through bone density scans and physical assessments. Long-term benefits include improved mobility and reduced risk of osteoporosis.
Surgery is indicated for patients with symptomatic hypercalcemia or significant bone loss. The procedure involves the removal of overactive parathyroid glands. Expected benefits include normalization of calcium levels and symptom relief. Risks include potential damage to surrounding structures and hypocalcemia. Post-operative care includes calcium and vitamin D supplementation.
The care team includes endocrinologists, surgeons, dietitians, and mental health professionals. Interventions focus on dietary management, symptom control, and psychological support. Strategies include stress management and family education about the condition. Families are educated on recognizing symptoms and managing dietary calcium intake. Long-term monitoring involves regular follow-ups to assess calcium levels and bone health.
When to See a Doctor for Familial isolated hyperparathyroidism
- Severe abdominal pain — this could indicate acute pancreatitis, a potential complication of hyperparathyroidism requiring immediate medical attention.
- Sudden onset of confusion or lethargy — these symptoms may suggest hypercalcemic crisis, a life-threatening condition that needs urgent treatment.
- Severe bone pain or fractures — this may signal significant bone demineralization due to prolonged high calcium levels, necessitating emergency care.
- Persistent fatigue — this could indicate chronic hypercalcemia affecting energy levels and should be evaluated by a healthcare provider.
- Frequent urination or excessive thirst — these symptoms may suggest hypercalcemia affecting kidney function and warrant medical assessment.
- Mild depression or mood changes — these could be related to calcium imbalance and should be discussed with a doctor for appropriate management.
- Mild muscle weakness — monitor for any progression and discuss with your doctor during routine visits.
- Occasional headaches — keep track of frequency and severity to report to your healthcare provider if they worsen.
Familial isolated hyperparathyroidism — Frequently Asked Questions
Is this condition hereditary?
Familial isolated hyperparathyroidism is typically inherited in an autosomal dominant pattern. This means there is a 50% chance of passing the condition to offspring. De novo mutations can occur, although they are less common. Individuals who carry the gene mutation may or may not show symptoms, which complicates carrier status. Genetic counseling is recommended to understand inheritance risks and family planning options.
What is the life expectancy for someone with this condition?
Life expectancy can vary depending on the age of onset and severity of the condition. Early diagnosis and management of calcium levels can significantly improve outcomes. Untreated, the condition can lead to complications such as kidney stones or cardiovascular issues, which can affect mortality. Effective treatment, including surgery or medication, can help maintain a normal lifespan. Patients should have realistic expectations about managing symptoms and potential complications.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of blood tests to check calcium and parathyroid hormone levels, genetic testing, and imaging studies. The time from first symptoms to diagnosis can vary, often taking months to years due to symptom overlap with other conditions. Endocrinologists are typically consulted for diagnosis and management. Delayed diagnosis is common due to the nonspecific nature of early symptoms. Genetic testing can confirm the diagnosis, especially in familial cases.
Are there any new treatments or clinical trials available?
Current research is exploring gene therapy and novel medications targeting calcium regulation. Clinical trials can be found on ClinicalTrials.gov by searching for hyperparathyroidism or related terms. Patients should discuss potential trial participation with their doctor, considering eligibility and potential benefits. New treatments are on the horizon, but widespread availability may take several years. Staying informed about research developments is crucial for accessing new therapies.
How does this condition affect daily life and activities?
The condition can impact mobility and self-care due to muscle weakness and bone pain. Educational and occupational activities may be affected by fatigue and concentration difficulties. Social and emotional challenges include coping with chronic illness and potential stigma. Family members may experience a significant caregiving burden, requiring support and resources. Adaptations such as physical therapy and counseling can help manage daily life effectively.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds.
Simonds WF, James-Newton LA, Agarwal SK et al. · Medicine (Baltimore) · 2002 · PMID: 11807402
- 2.New Concepts About Familial Isolated Hyperparathyroidism.
Marx SJ · J Clin Endocrinol Metab · 2019 · PMID: 30848815
- 3.Familial hyperparathyroidism.
Takami H, Shirahama S, Ikeda Y et al. · Biomed Pharmacother · 2000 · PMID: 10914986
- 4.Whole exome sequencing in familial isolated primary hyperparathyroidism.
Cetani F, Pardi E, Aretini P et al. · J Endocrinol Invest · 2020 · PMID: 31486992
- 5.Hereditary Primary Hyperparathyroidism.
Newey PJ · Endocrinol Metab Clin North Am · 2021 · PMID: 34774240
- 6.Management of familial hyperparathyroidism syndromes: MEN1, MEN2, MEN4, HPT-Jaw tumour, Familial isolated hyperparathyroidism, FHH, and neonatal severe hyperparathyroidism.
Cristina EV, Alberto F · Best Pract Res Clin Endocrinol Metab · 2018 · PMID: 30665551
- 7.[Familial isolated hyperparathyroidism: a report of two cases].
Matsuki T, Nishiura H, Jo Y et al. · Nihon Hinyokika Gakkai Zasshi · 2000 · PMID: 10689881
- 8.GCM2 p.Tyr394Ser variant in Ashkenazi Israeli patients with suspected familial isolated hyperparathyroidism.
Szalat A, Shpitzen S, Pollack R et al. · Front Endocrinol (Lausanne) · 2023 · PMID: 38130397
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-01